Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial
BACKGROUND: Clinical trials in heart failure (HF) traditionally use time-to-event analyses focusing on death and hospitalization for HF. These time-to-first event analyses may have more limited abilities to assess the probability of benefiting from a therapy, especially if that benefit manifests as improved functional status rather than reduced risk of death or HF hospitalization. Hierarchical end points including clinical outcomes and patient status measures allow for ranked evaluation of outcomes in 1 metric assessing whether patients randomized to intervention or control are more likely to derive an overall benefit while also allowing more patients to contribute to the primary outcome.
METHODS: We review the rationale for using hierarchical end points in HF trials, provide examples of HF trials that used this type of end point, and discuss its use in the HEART-FID trial (Randomized Placebo-Controlled Trial of Ferric Carboxymaltose as Treatment for Heart Failure With Iron Deficiency), the largest HF trial to date implementing a hierarchical end point analysis for the primary outcome.
RESULTS: Using a hierarchical end point as the primary outcome allows for the inclusion of different types of outcomes in 1 ranked end point, making it possible to more holistically assess the potential utility of a new therapy on patient well-being and outcomes.
CONCLUSIONS: Hierarchical end points assess the potential utility of a new therapy on patient well-being and outcome more holistically than time-to-first event analysis. Trials that would not have been feasible due to decreasing rates of death and hospitalization in the HF population can use hierarchical end points to successfully power studies to identify promising HF therapies. The HEART-FID trial used hierarchical end points to better determine the role of intravenous ferric carboxymaltose in patients with HF.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03037931.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Circulation. Heart failure - 17(2024), 2 vom: 01. Feb., Seite e010676 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Harrington, Josephine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6897GXD6OE |
|---|
| Anmerkungen: |
Date Completed 22.02.2024 Date Revised 01.04.2024 published: Print-Electronic ClinicalTrials.gov: NCT03037931 Citation Status MEDLINE |
|---|
| doi: |
10.1161/CIRCHEARTFAILURE.123.010676 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367412993 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367412993 | ||
| 003 | DE-627 | ||
| 005 | 20240403000109.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240122s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIRCHEARTFAILURE.123.010676 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1361.xml |
| 035 | |a (DE-627)NLM367412993 | ||
| 035 | |a (NLM)38250799 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Harrington, Josephine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2024 | ||
| 500 | |a Date Revised 01.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03037931 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Clinical trials in heart failure (HF) traditionally use time-to-event analyses focusing on death and hospitalization for HF. These time-to-first event analyses may have more limited abilities to assess the probability of benefiting from a therapy, especially if that benefit manifests as improved functional status rather than reduced risk of death or HF hospitalization. Hierarchical end points including clinical outcomes and patient status measures allow for ranked evaluation of outcomes in 1 metric assessing whether patients randomized to intervention or control are more likely to derive an overall benefit while also allowing more patients to contribute to the primary outcome | ||
| 520 | |a METHODS: We review the rationale for using hierarchical end points in HF trials, provide examples of HF trials that used this type of end point, and discuss its use in the HEART-FID trial (Randomized Placebo-Controlled Trial of Ferric Carboxymaltose as Treatment for Heart Failure With Iron Deficiency), the largest HF trial to date implementing a hierarchical end point analysis for the primary outcome | ||
| 520 | |a RESULTS: Using a hierarchical end point as the primary outcome allows for the inclusion of different types of outcomes in 1 ranked end point, making it possible to more holistically assess the potential utility of a new therapy on patient well-being and outcomes | ||
| 520 | |a CONCLUSIONS: Hierarchical end points assess the potential utility of a new therapy on patient well-being and outcome more holistically than time-to-first event analysis. Trials that would not have been feasible due to decreasing rates of death and hospitalization in the HF population can use hierarchical end points to successfully power studies to identify promising HF therapies. The HEART-FID trial used hierarchical end points to better determine the role of intravenous ferric carboxymaltose in patients with HF | ||
| 520 | |a REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03037931 | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a clinical trial | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a iron | |
| 650 | 7 | |a ferric carboxymaltose |2 NLM | |
| 650 | 7 | |a 6897GXD6OE |2 NLM | |
| 650 | 7 | |a Ferric Compounds |2 NLM | |
| 650 | 7 | |a Maltose |2 NLM | |
| 650 | 7 | |a 69-79-4 |2 NLM | |
| 700 | 1 | |a Mentz, Robert J |e verfasserin |4 aut | |
| 700 | 1 | |a Rockhold, Frank W |e verfasserin |4 aut | |
| 700 | 1 | |a Garg, Jyotsna |e verfasserin |4 aut | |
| 700 | 1 | |a Butler, Javed |e verfasserin |4 aut | |
| 700 | 1 | |a De Pasquale, Carmine G |e verfasserin |4 aut | |
| 700 | 1 | |a Ezekowitz, Justin A |e verfasserin |4 aut | |
| 700 | 1 | |a Lewis, Gregory D |e verfasserin |4 aut | |
| 700 | 1 | |a O'Meara, Eileen |e verfasserin |4 aut | |
| 700 | 1 | |a Ponikowski, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a Troughton, Richard W |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Yee W |e verfasserin |4 aut | |
| 700 | 1 | |a Adamczyk, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Storie, Tatyana |e verfasserin |4 aut | |
| 700 | 1 | |a Blackman, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Hernandez, Adrian F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation. Heart failure |d 2008 |g 17(2024), 2 vom: 01. Feb., Seite e010676 |w (DE-627)NLM187215812 |x 1941-3297 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2024 |g number:2 |g day:01 |g month:02 |g pages:e010676 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/CIRCHEARTFAILURE.123.010676 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2024 |e 2 |b 01 |c 02 |h e010676 | ||